|
Balance Sheet Cash Flow Statement 6455 Nancy Ridge Dr. San Diego, CA 92121-2249 CA Tel. 858-452-6600 Fax 858-626-2851 |
Type: Public
On the web:
http://www.ljpc.com
Employees:
94
La Jolla Pharmaceutical aimed to eliminate diseases. The development-stage firm was working with Toleragens, proprietary therapies that block the abnormal antibody production associated with certain autoimmune disorders without suppressing the entire immune system. Its lead drug candidate was Riquent, a treatment for renal disease associated with lupus. The drug would have been one of the few new drugs for lupus. La Jolla was also exploring the use of Toleragens to fight other autoimmune disorders such as antibody-mediated stroke and deep vein thrombosis. The company ceased most of its operations and announced plans to liquidate after trials of Riquent failed in 2009.
Key numbers for fiscal year ending December, 2008:
Sales: $0.0M
Net income: ($62.9)M
Officers:
Chairman: Craig R. Smith
President, CEO, Assistant Secretary, and Director: Deirdre Y. Gillespie
VP Finance and Secretary: Gail A. Sloan
Competitors:
Alexion Pharmaceuticals
Biogen Idec
Immunomedics
